Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (1542)	11/8/1999 9:12:00 PM
From: Mark Marcellus	Read Replies (3) \| Respond to of 5582

If Zicam works for the masses as well as it works for the people that I know, it won't matter if GumTech or Edelman did a no-no. Dan - Regardless of the "facts" you discover in your investigation of this mess, I think we're still left with a choice between the two scenarios I gave a few days ago. It's either your "worst case" scenario above, or Zicam management screwed up big time. That leaves us with the same questions. If it's the worst case, why should we believe anything GUMM tells shareholders when they were willing to lead AJIC down the primrose path just to get a headline. And if it's a screw-up, how can we expect them to successfully compete against the big drug and consumer products companies (some of the savviest marketers on the planet) when they botch something this simple?